GLP-1 Drugs: FDA Removes Semaglutide from the Drug Shortage List
On February 21, 2025, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order determining that the semaglutide drug shortage has been resolved. The timing of this order was unexpected due to the ongoing litigation between FDA and the Outsourcing Facilities Association (OFA) involving tirzepatide,
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...
The U.S. FDA announced Friday that it would refrain from penalizing makers of compounded versions of Novo Nordisk’s (NVO) weight loss/obesity drugs as supply conditions for the GLP-1s improve after an ...
Many of these unlawful and unauthorized shipments were explicitly tagged for compounding, which in turn could put many ...
More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback